title: Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
abstract: Lenvatinib, an oral multikinase inhibitor, was approved by the US Food and Drug Administration in February 2015. In a pivotal phase III study of 392 patients with progressive radioiodine-refractory thyroid cancer, the overall response rate of patients receiving lenvatinib was 64.8%, with complete response in four patients. The median progression-free survival was 18.3 months in the lenvatinib arm versus 3.6 months in patients receiving placebo. Median overall survival was not reached in either arm. Lenvatinib is a promising new treatment for patients with radioiodine (iodine-131)-refractory differentiated thyroid cancer.
authors.affiliation: 1 St Joseph Regional Cancer and Blood Institute, Lewiston, ID, USA.
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Hewett
authors.affiliation: 1 St Joseph Regional Cancer and Blood Institute, Lewiston, ID, USA.
authors.forename: Subash
authors.initials: S
authors.lastname: Ghimire
authors.affiliation: 2 Department of Medicine, Mercer University, Macon, GA, USA.
authors.forename: Bilal
authors.initials: B
authors.lastname: Farooqi
authors.affiliation: 3 North Puget Cancer Center, Sedro-Woolley, WA, USA.
authors.forename: Binay K
authors.initials: BK
authors.lastname: Shah
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011804:Quinolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011804:Quinolines; C531958:lenvatinib
keywords: Differentiated thyroid cancer; lenvatinib; tyrosine kinase inhibitor